Answers are grounded in this paper and cite their sources.
Clinical study reports long-term response durability in metastatic renal cell carcinoma, highlighting the therapeutic efficacy of high-dose interleukin-2.
Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.8.2410 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8708739 Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. G A FyfexG A FyfeSearch for articles by this author , R I FisherxR I FisherSearch for articles by this author , S A RosenbergxS A RosenbergSearch for articles by this author , M SznolxM SznolSearch for articles by this author , D R ParkinsonxD R ParkinsonSearch for articles by this author , A C LouiexA C LouieSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.8.2410 PDF "Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.." Journal of Clinical Oncology, 14(8), pp. 2410–2411© 1996 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
Fyfe et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: